Archive for Abstracts

First-in-human Phase 1/2a Trial of a Macrocyclic ATR inhibitor (ATRN-119) in Patients with Advanced Solid Tumors.

Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors

First-in-human results of STX-478, a mutant-selective PI3Kα inhibitor, in advanced solid tumor patients

First-in-Human Phase I Dose Escalation Study of ALG.APV-527, a 5T4 Tumor Antigen-Conditional 4-1BB Bispecific Antibody, in Patients with Advanced Solid Tumors, Demonstrates Positive Safety, Signals of Biological Activity and Patients with Lasting Stable Disease

Trial in progress: A phase 1/2a trial of Aurora-A inhibitor (JAB-2485) in adult patients with advanced solid tumors

A Phase 1/2 study of Rinatabart Sesutecan (Rina-S) in Patients With Advanced Ovarian or Endometrial Cancer

Dazostinag (TAK-676) alone and in combination with pembrolizumab in patients with advanced/metastatic solid tumors: Data from phase 1 dose escalation

Phase 1/2 Trial of ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, in Patients With Advanced Solid Tumors

Updated data from BeamionLUNG-1, a Phase Ia/b trial of the HER2-specific tyrosine kinase inhibitor, zongertinib(BI 1810631), in patients with HER2 mutation-positive NSCLC

First-in-human trial of the oral first-in-class Ubiquitin Specific Peptidase 1 (USP1) inhibitor RO7623066 (KSQ-4279), given as single agent and in combination with olaparib or carboplatin in patients with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations

« Older Entries